Clinical trial · Observational
A Risk Assessment Tool to Increase Statin Use Among High Risk Cancer Survivors: Development and Pilot Testing
NCT02895880CI-TRIAL-00045564completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to collect initial data on what survivors of childhood, adolescent, and young adult cancer think of how information about statins is communicated. Statins are medications that lower cholesterol. The results of this study will be used to improve the communication about statins. This is to aid patients and their providers in making health care decisions together, also known as shared decision making.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer Survivors | — | UNRESOLVED | — |
| Statin Use Among High Risk Survivors | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| statin communication tool | Behavioral | — | UNRESOLVED |
| usual care | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- usual care
- description
- first 25 participants will receive usual care (i.e. no risk communication tool)
- interventionNames
- Behavioral: usual care
- label
- risk communication tool
- description
- next 25 participants, clinicians will use the risk communication tool in their discussion about statins and cardiovascular risk reduction
- interventionNames
- Behavioral: statin communication tool
Primary outcomes (1)
- measure
- number of patients who initiated statins after the office visit
- timeFrame
- 1 year
- description
- This data will allow validation of the adapted tool in the cancer survivor population. Acceptability will be estimated using the tool describe which will be transformed to a 0 to 100 scale and summarized separately in the two populations using means and standard deviations.These preliminary statistics in both populations (intervention and usual care) will be utilized to design a future larger scale study powered to detect a difference between the two groups.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 25 Years
Show eligibility criteria text
Inclusion Criteria: * English speaking * A personal history of cancer, tumor, or a related illness * Followed in the Adult Long Term Follow Up Program * Received ≥ 2000 cGy radiation to the heart/chest * ≥Ten years post-radiation therapy to the heart/chest * Age ≥ 25 years old Exclusion Criteria: * Evidence of active progression of disease or recurrence * Neurocognitive deficits that impair ability to give informed consent * Current use of a statin * Diagnosis of another primary cancer for which the patient is currently undergoing radiation therapy chemotherapy, or bone marrow transplant * Diagnosis of CVD with or without current statin use
References
Publications (0)
Data not yet available
No reference posted for this study.